{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-04T20:39:34.071214+00:00","company":{"ticker":"CODX","cik":1692415,"company_name":"Co-Diagnostics, Inc."},"pagination":{"limit":100,"returned":6,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"405f49fd18e20b010ea2a69b739449cf5fca51da","cik":1692415,"ticker":"CODX","company_name":"Co-Diagnostics, Inc.","filed_at":"2026-03-31T23:59:59+00:00","payload":{"eps_text":"$35.25 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss of $46.9 million","period_text":"full year ended December 31, 2025","report_date":"2026-03-31","result_type":"reported_results","revenue_text":"$0.6 million"},"claim":"Co-Diagnostics, Inc. reported full year ended December 31, 2025 results: revenue $0.6 million, net income net loss of $46.9 million, EPS $35.25 per share.","evidence_excerpt":"the development of molecular\ndiagnostic tests, today announced its financial results for the full year ended December 31, 2025. Full\nYear 2025 Financial Results: ● Revenue\n of $0.6 million, compared to $3.9 million in 2024, primarily due to lower grant revenue ● Operating\n expenses of $50.6 million, compared to $43.0 million in 2024, driven by a non-cash impairment","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-014129","anchor_url":"https://secwatch.observer/filing/0001493152-26-014129#claim-405f49fd18e20b010ea2a69b739449cf5fca51da","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1692415/000149315226014129/0001493152-26-014129-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"261b568cd7b2030ed2d81edf468a4a8fc6e8b314","cik":1692415,"ticker":"CODX","company_name":"Co-Diagnostics, Inc.","filed_at":"2026-01-13T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"delisting_pending","cure_deadline":null,"deficiency_type":"minimum_bid_price","delisting_effective_date":"2026-01-14","exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2026-01-07","notice_type":"delisting_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)","5815(a)(1)(B)(ii)(d)"],"rules_cited_in_text":true},"claim":"Co-Diagnostics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5815(a)(1)(B)(ii)(d)).","evidence_excerpt":"January 7, 2026, Co-Diagnostics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing\nQualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that\nthe Staff had determined to delist the Company’s common stock from The Nasdaq Capital Market due to the Company’s continued\nnon-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”). The Company\nplans to timely request a hearing before the Nasdaq Hearings Panel to address the bid price deficiency; however, the Company’s\nsecuri","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-001971","anchor_url":"https://secwatch.observer/filing/0001493152-26-001971#claim-261b568cd7b2030ed2d81edf468a4a8fc6e8b314","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1692415/000149315226001971/0001493152-26-001971-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"0a6143b4dd21a6bca9c36182a4c03b86500de75c","cik":1692415,"ticker":"CODX","company_name":"Co-Diagnostics, Inc.","filed_at":"2025-01-10T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":null,"deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-01-10","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)"]},"claim":"Co-Diagnostics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"January 10, 2025, Co-Diagnostics, Inc. (“CODX” or “the Company”) received a notice from Nasdaq Listing Qualifications\ndepartment (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the closing bid price","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-25-001705","anchor_url":"https://secwatch.observer/filing/0001493152-25-001705#claim-0a6143b4dd21a6bca9c36182a4c03b86500de75c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1692415/000149315225001705/0001493152-25-001705-index.htm"},{"fact_type":"earnings_release","fact_key":"ac4c1b851207eace2e2eddfc41f14f0891e7591b","cik":1692415,"ticker":"CODX","company_name":"Co-Diagnostics, Inc.","filed_at":"2024-05-09T23:59:59+00:00","payload":{"eps_text":"loss of $0.31 per fully diluted share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss of $9.3 million","period_text":"quarter ended March 31, 2024","report_date":"2024-05-09","result_type":"reported_results","revenue_text":"$0.5 million"},"claim":"Co-Diagnostics, Inc. reported quarter ended March 31, 2024 results: revenue $0.5 million, net income Net loss of $9.3 million, EPS loss of $0.31 per fully diluted share.","evidence_excerpt":"Co-Diagnostics, Inc. Reports First Quarter 2024 Financial Results SALT LAKE CITY, May 9, 2024— Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Dx,” or the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended March 31, 2024. First Quarter 2024 Financial Results: ● Revenue of $0.5 million, down from $0.6 million during the prior year. Grant revenue totaled $0.2 million while product revenue totaled $0.3 million ● Operating expenses of $10.5 million increased by 4.4% from the prior year due to an increase in research and development costs incurred for the development of tests currently in our pipeline ● Operating loss of $10.3 million compared to operating loss of $10.0 million in Q1 2023 ● Net loss of $9.3 million, compared to net loss of $5.8 million in the prior year, representing a loss of $0.31 per fully diluted share, compared to a loss of $0.20 per fully dilut","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-018418","anchor_url":"https://secwatch.observer/filing/0001493152-24-018418#claim-ac4c1b851207eace2e2eddfc41f14f0891e7591b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1692415/000149315224018418/0001493152-24-018418-index.htm"},{"fact_type":"executive_change","fact_key":"d47559aa2b","cik":1692415,"ticker":"CODX","company_name":"Co-Diagnostics, Inc.","filed_at":"2024-03-15T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-03-15","interim":false,"role":"President","role_category":"president","successor_name":null,"successor_named":false},"claim":"Richard Abbott was appointed as President at Co-Diagnostics, Inc..","evidence_excerpt":"On March 15, 2024, the Board of Directors of Co-Diagnostics, Inc. (the “Company”) appointed Richard Abbott as President.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001493152-24-010089","anchor_url":"https://secwatch.observer/filing/0001493152-24-010089#claim-d47559aa2b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1692415/000149315224010089/0001493152-24-010089-index.htm"},{"fact_type":"earnings_release","fact_key":"e1c7632a0dfc78fc5fb54c0852581f83dd297ff9","cik":1692415,"ticker":"CODX","company_name":"Co-Diagnostics, Inc.","filed_at":"2024-03-14T23:59:59+00:00","payload":{"eps_text":"a loss of $1.20 per fully diluted share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss of $35.3 million","period_text":"the full year ended December 31, 2023","report_date":"2024-03-14","result_type":"reported_results","revenue_text":"$6.8 million"},"claim":"Co-Diagnostics, Inc. reported the full year ended December 31, 2023 results: revenue $6.8 million, net income Net loss of $35.3 million, EPS a loss of $1.20 per fully diluted share.","evidence_excerpt":"the development of molecular diagnostic tests, today announced financial results for the full year ended December 31, 2023. Full\nYear 2023 Financial Results: ● Revenue\n of $6.8 million, down from $34.2 million during the prior year primarily due to the decline in global demand for the Logix Smart®\n COVID-19 tests. Grant revenue totaled $5.8 million while","confidence":0.97,"filing_url":"https://secwatch.observer/filing/0001493152-24-009950","anchor_url":"https://secwatch.observer/filing/0001493152-24-009950#claim-e1c7632a0dfc78fc5fb54c0852581f83dd297ff9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1692415/000149315224009950/0001493152-24-009950-index.htm"}]}